Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007455 | 1.00 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL30852356 | 1.00 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL31258991 | 1.00 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL1167928 | 1.00 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL1167927 | 0.99 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL18185314 | 0.99 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL1167925 | 0.99 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6423830 | 0.96 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL12966393 | 0.96 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6423829 | 0.96 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102093578-A | Preparation method of shape-controllable amino-acid ester (with side group benzene ring) substituted polyphosphazene microspheres | UNIV BEIJING CHEMICAL | 2011-06-15 | — | — | CN | claimed |
| CN-101048139-A | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LAB INC (US) | 2007-10-03 | — | — | CN | claimed |
| CN-120019060-A | Compounds and their use for filtering ultraviolet and/or high-energy visible light | 索利奥美公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9211249-B2 | Methods and compositions for transdermal delivery of caffeine in the form of solutions or suspensions | SPRAYABLE HOLDINGS, INC. | 2015-12-15 | — | — | US | disclosed |
| US-9175006-B2 | Compositions and methods for cyclofructans as separation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| CN-102725284-A | Compound suitable for the treatment of synucleopathies | NEUROPORE THERAPIES INC | 2012-10-10 | — | — | CN | disclosed |
| EP-2443127-A2 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | Board of Regents, The University of Texas System (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011084642-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084642-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| CN-102093578-A | Preparation method of shape-controllable amino-acid ester (with side group benzene ring) substituted polyphosphazene microspheres | UNIV BEIJING CHEMICAL | 2011-06-15 | — | — | CN | disclosed |
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-02-03 | — | — | US | disclosed |
| WO-2010148191-A2 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-12-23 | — | — | WO | disclosed |
| CN-101048139-A | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LAB INC (US) | 2007-10-03 | — | — | CN | disclosed |
| US-20060079497-A1 | Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues | BALL STATE UNIVERSITY | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | PAICS, DCXR, PFAS | TACR1 869/4885MAPT 1797/4885KDM4E 4235/4885 |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | MTNR1A, MTNR1B, CYP27B1 | TACR1 1032/4885MAPT 2224/4885KDM4E 2385/4885 |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | SNCA, HTT, MAPT | TACR1 3345/4885MAPT 3/4885KDM4E 3670/4885 |
| US-20060079497-A1 | Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues | MCL1, LSS, MRPS18A | TACR1 4685/4885MAPT 4317/4885KDM4E 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.